Susan M Christner

Susan M Christner

UNVERIFIED PROFILE

Are you Susan M Christner?   Register this Author

Register author
Susan M Christner

Susan M Christner

Publications by authors named "Susan M Christner"

Are you Susan M Christner?   Register this Author

21Publications

521Reads

8Profile Views

Quantitation of paclitaxel, and its 6-alpha-OH and 3-para-OH metabolites in human plasma by LC-MS/MS.

J Pharm Biomed Anal 2019 Aug 15;172:26-32. Epub 2019 Apr 15.

Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, United States; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, United States. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S07317085183240
Publisher Site
http://dx.doi.org/10.1016/j.jpba.2019.04.027DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548629PMC
August 2019

A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer.

Cancer Chemother Pharmacol 2019 Mar 8;83(3):473-482. Epub 2018 Dec 8.

Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, VA, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-018-3749-7
Publisher Site
http://dx.doi.org/10.1007/s00280-018-3749-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628688PMC
March 2019

A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia.

Leuk Lymphoma 2018 11 4;59(11):2595-2601. Epub 2018 Apr 4.

b Division of Hematology-Oncology, Department of Medicine , University of Pittsburgh School of Medicine , Pittsburgh , PA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1443330DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201295PMC
November 2018

Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.

Br J Clin Pharmacol 2015 Nov 19;80(5):1097-108. Epub 2015 Sep 19.

Department of Pharmaceutical Sciences, School of Pharmacy, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bcp.12723DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631182PMC
November 2015

An Automated Homogeneous Immunoassay for Quantitating Imatinib Concentrations in Plasma.

Ther Drug Monit 2015 Aug;37(4):486-92

*Cancer Therapeutics Program, University of Pittsburgh Cancer Institute; †Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy; and ‡Research and Development, Saladax Biomedical, Inc, Bethlehem, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FTD.0000000000000178DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486633PMC
August 2015

In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of pyrazole-based small molecule inhibitors of Mdm2/4-p53 interaction.

Cancer Chemother Pharmacol 2015 Aug 7;76(2):287-99. Epub 2015 Jun 7.

Cancer Therapeutics Program, Hillman Cancer Center, The University of Pittsburgh Cancer Institute, Room G27b, 5117 Centre Ave, Pittsburgh, PA, 15213, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2791-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5033042PMC
August 2015

Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627).

Neuro Oncol 2015 Jul 10;17(7):992-8. Epub 2015 Mar 10.

Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York (A.B.L. current); Memorial Sloan Kettering Cancer Center, New York, New York (A.B.L. during accrual, L.M.D.); NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania (S.L.P., S.G., M.W); The University of Texas MD Anderson Cancer Center, Houston, Texas (M.R.G., K.D.A. during accrual; R.K.); Neuro-Oncology Branch, National Cancer Institute/National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland (M.R.G. current); University of Toronto and Princess Margaret Cancer Centre, Toronto, Canada (K.D.A. current); Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania (J.H.B., S.M.C.); Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy Pittsburgh, Pennsylvania (J.H.B.); NCI Community Oncology Research Program - Kansas City, Prairie Village, Kansas (R.G.); Arizona Oncology Services Foundation, Tucson, Arizona (E.Y.); Penn State University and The Milton S. Hershey Medical Center, Hershey, Pennsylvania (H.W.); University of Maryland Medical Systems, Baltimore, Maryland (M.P.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762006PMC
July 2015

Potential interactions between HIV drugs, ritonavir and efavirenz and anticancer drug, nilotinib--a study in primary cultures of human hepatocytes that is applicable to HIV patients with cancer.

J Clin Pharmacol 2014 Nov 27;54(11):1272-9. Epub 2014 May 27.

Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcph.333DOI Listing
November 2014

Quantitative method for the determination of iso-fludelone (KOS-1803) in human plasma by LC-MS/MS.

J Pharm Biomed Anal 2014 Nov 12;100:199-204. Epub 2014 Aug 12.

Molecular Therapeutics/Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA; Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA 15213, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S07317085140037
Publisher Site
http://dx.doi.org/10.1016/j.jpba.2014.08.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4179924PMC
November 2014

ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy.

Clin Cancer Res 2014 May 19;20(10):2703-13. Epub 2014 Mar 19.

Authors' Affiliations: General Clinical Lab/Mouse Cancer Clinic, The Netherlands Cancer Institute; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam; Division of Drug Toxicology, Faculty of Pharmacy; Utrecht University, Utrecht; Molecular Therapeutics/Drug Discovery Program, University of Pittsburgh Cancer Institute; Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania; Neuro-oncology Research Group, Departments of Neurosurgery and Pediatric Oncology/Hematology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, the Netherlands; and Molecular Neurogenetics Unit, Departments of Neurology and Radiology, Massachusetts General Hospital, and Neuroscience Program, Harvard Medical School, Boston, Massachusetts

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-0084DOI Listing
May 2014

Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers.

Cancer Chemother Pharmacol 2014 Jan 30;73(1):207-11. Epub 2013 Oct 30.

Molecular Therapeutics/Drug Discovery Program, University of Pittsburgh Cancer Institute, Hillman Research Pavilion, Room G27E, 5117 Centre Avenue, Pittsburgh, PA, 15213-1863, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2337-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880632PMC
January 2014

Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers.

Cancer Chemother Pharmacol 2013 Nov 14;72(5):1143-7. Epub 2013 Sep 14.

Molecular Therapeutics/Drug Discovery Program, University of Pittsburgh Cancer Institute, Hillman Research Pavilion, Room G27D, 5117 Centre Avenue, Pittsburgh, PA, 15213-1863, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2283-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3818249PMC
November 2013

Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.

Drug Metab Dispos 2013 Oct 2;41(10):1843-51. Epub 2013 Aug 2.

Department of Pharmaceutical Sciences and Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania (V.C.P., R.V.); Molecular Therapeutics Drug Discovery program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania (R.A.P., S.M.C., J.H.B.); Division of Pathology, Department of Laboratory Medicine, Karolinska Institutet and Hospital, Stockholm, Sweden (R.G., S.C.S.); and The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland (M.A.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.113.052100DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3781374PMC
October 2013

Effect of a proton pump inhibitor on the pharmacokinetics of imatinib.

Br J Clin Pharmacol 2009 Sep;68(3):370-4

Molecular Therapeutics/Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213-1863, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2125.2009.03466.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2766475PMC
September 2009

A high-performance liquid chromatography-mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serum.

J Chromatogr B Analyt Technol Biomed Life Sci 2009 Jul 21;877(20-21):1894-900. Epub 2009 May 21.

Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA 15213, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jchromb.2009.05.034DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2759677PMC
July 2009